Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2019

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	Fiscal Year Ended June 30,
Medical Indication	2019		2018		2017
Antibiotic	$	15,391	$	14,509	$	16,748
Anti-Psychosis		73,453		59,557		58,625
Cardiovascular		101,467		64,011		50,628
Central Nervous System		34,170		31,789		39,451
Gallstone		9,604		20,280		48,600
Gastrointestinal		48,566		60,294		71,887
Glaucoma		3,021		6,540		18,763
Migraine		41,592		54,015		29,014
Muscle Relaxant		12,344		13,496		13,636
Pain Management		28,210		23,036		26,135
Respiratory		3,418		7,891		10,516
Thyroid Deficiency		197,522		245,929		174,005
Urinary		6,783		8,661		14,695
Other		56,507		54,720		47,196
Contract manufacturing revenue		23,359		19,835		17,442
Net sales		655,407		684,563		637,341
Settlement agreement		—		—		(4,000)
Total net sales	$	655,407	$	684,563	$	633,341

Summary of products which accounted for at least 10% of total net sales

	June 30,		June 30,		June 30,
	2019		2018		2017
Product 1	30	%	36	%	27	%
Product 2	10	%	8	%	9	%

Summary of customers which accounted for at least 10% of total net sales

	June 30,		June 30,		June 30,
	2019		2018		2017
Customer A	21	%	29	%	28	%
Customer B	18	%	17	%	21	%
Customer C	12	%	—	%	—	%
Customer D	10	%	5	%	6	%